Drug patent protection: it's time for a 'one-and-done' approach - STAT

Drug patent protection: it's time for a 'one-and-done' approach - STAT

Opinion: ‘One-and-done’ for new drugs could cut patent thickets and boost generic competition

By ROBIN FELDMAN

ADOBE

That approach to drug patents that gives companies a single period of exclusivity could prevent the patent thickets that stifle generic competition.

READ MORE